- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05638295
Testando o uso de AMG 510 (Sotorasib) e Panitumumab como um tratamento direcionado para cânceres tumorais sólidos mutantes KRAS G12C (um estudo de tratamento ComboMATCH)
Um estudo randomizado de fase II de AMG 510 (Sotorasib) com ou sem panitumumabe em tumores sólidos avançados: um estudo de tratamento ComboMATCH
This phase II ComboMATCH treatment trial tests how well AMG 510 (sotorasib) with or without panitumumab works in treating patients with KRAS G12C mutant solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Sotorasib is in a class of medications called KRAS inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells. Panitumumab is in a class of medications called monoclonal antibodies. It works by slowing or stopping the growth of cancer cells. Giving combination panitumumab and sotorasib may kill more tumor cells in patients with advanced solid tumors with KRAS G12C mutation.
Visão geral do estudo
Status
Descrição detalhada
PRIMARY OBJECTIVES:
I. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab as compared to AMG 510 (sotorasib) alone in patients with advanced/metastatic KRAS G12C mutated solid tumors (except colorectal carcinoma [CRC] and non-small cell lung carcinoma [NSCLC]) as measured by progression free survival (Cohort 1).
II. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab in patients with advanced/metastatic KRAS G12C mutated solid tumors that have progressed on a prior KRAS G12C inhibitor as measured by response rate (Cohort 2).
SECONDARY OBJECTIVES:
I. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab as compared to AMG 510 alone in patients with advanced/metastatic KRAS G12C mutated solid tumors (except CRC and NSCLC) as measured by response rate, disease control rate, and overall survival (Cohort 1).
II, To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab in patients with advanced/metastatic KRAS G12C mutated solid tumors that have progressed on a prior KRAS G12C inhibitor as measured by disease control rate, progression free survival (PFS), and overall survival (Cohort 2).
III. To further evaluate the safety and tolerability of the combination of AMG 510 (sotorasib) and panitumumab.
IV. To collect tissue and provide it to the ComboMATCH Registration Protocol to assess concordance between the diagnostic tumor mutation profile generated by the Designated Laboratories, the pre-treatment biopsy mutation profile, and the pre-treatment circulating tumor-derived deoxyribonucleic acid (DNA) (ctDNA) mutation profile from plasma, as described in ComboMATCH Registration Protocol.
CORRELATIVE EXPLORATORY OBJECTIVES:
I. To investigate the impact of concomitant mutations on the clinical benefit. II. To evaluate if changes in circulating tumor DNA (ctDNA) over time correlate with response to treatment.
III. To evaluate the relative mutant allele fraction of KRAS mutation as a predictor of clinical benefit.
IV. To evaluate if ERK 1/2 and PI3K pathway activation correlate with response and/or resistance.
OUTLINE: Patients are assigned to 1 of 2 cohorts.
COHORT I: Patients who have never received a KRAS G12C inhibitor are randomized to arms A or B.
ARM A: Patients receive sotorasib orally (PO) once daily (QD) on days 1-28 and panitumumab intravenously (IV) on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and computed tomography (CT) or magnetic resonance imaging (MRI) on study.
ARM B: Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.
COHORT II: Patients who have received a KRAS G12C inhibitor are assigned to arm C.
ARM C: Patients receive combination therapy as in Arm A.
After completion of study treatment, patients are followed up at 30 days and then every 3-6 months for up to 36 months.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- University of Alabama at Birmingham Cancer Center
-
Mobile, Alabama, Estados Unidos, 36688
- University of South Alabama Mitchell Cancer Institute
-
-
California
-
Los Angeles, California, Estados Unidos, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Estados Unidos, 90025
- The Angeles Clinic and Research Institute - West Los Angeles Office
-
Palo Alto, California, Estados Unidos, 94304
- VA Palo Alto Health Care System
-
-
Florida
-
Aventura, Florida, Estados Unidos, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Coral Gables, Florida, Estados Unidos, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Coral Springs, Florida, Estados Unidos, 33065
- UM Sylvester Comprehensive Cancer Center at Coral Springs
-
Deerfield Beach, Florida, Estados Unidos, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Hollywood, Florida, Estados Unidos, 33021
- UM Sylvester Comprehensive Cancer Center at Hollywood
-
Jacksonville, Florida, Estados Unidos, 32224-9980
- Mayo Clinic in Florida
-
Miami, Florida, Estados Unidos, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Estados Unidos, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Estados Unidos, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Idaho
-
Boise, Idaho, Estados Unidos, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Estados Unidos, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Estados Unidos, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Estados Unidos, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Estados Unidos, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Estados Unidos, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Estados Unidos, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Estados Unidos, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Estados Unidos, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Estados Unidos, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
-
Illinois
-
Barrington, Illinois, Estados Unidos, 60010
- Advocate Good Shepherd Hospital
-
Chicago, Illinois, Estados Unidos, 60612
- University of Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- John H Stroger Jr Hospital of Cook County
-
Chicago, Illinois, Estados Unidos, 60657
- Advocate Illinois Masonic Medical Center
-
Crystal Lake, Illinois, Estados Unidos, 60014
- AMG Crystal Lake - Oncology
-
Danville, Illinois, Estados Unidos, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Estados Unidos, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Estados Unidos, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Downers Grove, Illinois, Estados Unidos, 60515
- Advocate Good Samaritan Hospital
-
Effingham, Illinois, Estados Unidos, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Estados Unidos, 62401
- Carle Physician Group-Effingham
-
Elgin, Illinois, Estados Unidos, 60123
- Advocate Sherman Hospital
-
Hazel Crest, Illinois, Estados Unidos, 60429
- Advocate South Suburban Hospital
-
Libertyville, Illinois, Estados Unidos, 60048
- Condell Memorial Hospital
-
Libertyville, Illinois, Estados Unidos, 60048
- AMG Libertyville - Oncology
-
Mattoon, Illinois, Estados Unidos, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, Estados Unidos, 60153
- Loyola University Medical Center
-
Normal, Illinois, Estados Unidos, 61761
- Carle Cancer Institute Normal
-
Normal, Illinois, Estados Unidos, 61761
- Carle BroMenn Medical Center
-
O'Fallon, Illinois, Estados Unidos, 62269
- Cancer Care Center of O'Fallon
-
Oak Lawn, Illinois, Estados Unidos, 60453-2699
- Advocate Christ Medical Center
-
Oak Lawn, Illinois, Estados Unidos, 60453
- Advocate Outpatient Center - Oak Lawn
-
Palos Heights, Illinois, Estados Unidos, 60463
- Advocate High Tech Medical Park
-
Park Ridge, Illinois, Estados Unidos, 60068
- Advocate Lutheran General Hospital
-
Shiloh, Illinois, Estados Unidos, 62269
- Memorial Hospital East
-
Springfield, Illinois, Estados Unidos, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Estados Unidos, 62702
- Springfield Clinic
-
Springfield, Illinois, Estados Unidos, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Estados Unidos, 61801
- Carle Cancer Center
-
-
Iowa
-
Ankeny, Iowa, Estados Unidos, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Des Moines, Iowa, Estados Unidos, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Estados Unidos, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Waukee, Iowa, Estados Unidos, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40536
- University of Kentucky/Markey Cancer Center
-
-
Maine
-
Brewer, Maine, Estados Unidos, 04412
- Lafayette Family Cancer Center-EMMC
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bethesda, Maryland, Estados Unidos, 20892
- National Institutes of Health Clinical Center
-
Bethesda, Maryland, Estados Unidos, 20889-5600
- Walter Reed National Military Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Estados Unidos, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Estados Unidos, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Estados Unidos, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Estados Unidos, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Estados Unidos, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Estados Unidos, 48118
- Chelsea Hospital
-
Dearborn, Michigan, Estados Unidos, 48124
- Corewell Health Dearborn Hospital
-
Farmington Hills, Michigan, Estados Unidos, 48336
- Corewell Health Farmington Hills Hospital
-
Flint, Michigan, Estados Unidos, 48503
- Hurley Medical Center
-
Flint, Michigan, Estados Unidos, 48503
- Genesee Hematology Oncology PC
-
Flint, Michigan, Estados Unidos, 48503
- Genesys Hurley Cancer Institute
-
Flint, Michigan, Estados Unidos, 48503
- Cancer Hematology Centers - Flint
-
Lansing, Michigan, Estados Unidos, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Estados Unidos, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Estados Unidos, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Royal Oak, Michigan, Estados Unidos, 48073
- Corewell Health William Beaumont University Hospital
-
Royal Oak, Michigan, Estados Unidos, 48073
- Corewell Health Children's
-
Saginaw, Michigan, Estados Unidos, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Estados Unidos, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, Estados Unidos, 48764
- MyMichigan Medical Center Tawas
-
Troy, Michigan, Estados Unidos, 48085
- Corewell Health Beaumont Troy Hospital
-
West Branch, Michigan, Estados Unidos, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Estados Unidos, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Ypsilanti, Michigan, Estados Unidos, 48106
- Huron Gastroenterology PC
-
-
Minnesota
-
Deer River, Minnesota, Estados Unidos, 56636
- Essentia Health - Deer River Clinic
-
Duluth, Minnesota, Estados Unidos, 55805
- Essentia Health Cancer Center
-
Hibbing, Minnesota, Estados Unidos, 55746
- Essentia Health Hibbing Clinic
-
Rochester, Minnesota, Estados Unidos, 55905
- Mayo Clinic in Rochester
-
Sandstone, Minnesota, Estados Unidos, 55072
- Essentia Health Sandstone
-
Virginia, Minnesota, Estados Unidos, 55792
- Essentia Health Virginia Clinic
-
-
Missouri
-
Cape Girardeau, Missouri, Estados Unidos, 63703
- Saint Francis Medical Center
-
City of Saint Peters, Missouri, Estados Unidos, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Estados Unidos, 63141
- Siteman Cancer Center at West County Hospital
-
St Louis, Missouri, Estados Unidos, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Estados Unidos, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Estados Unidos, 63136
- Siteman Cancer Center at Christian Hospital
-
-
Montana
-
Anaconda, Montana, Estados Unidos, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Estados Unidos, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Estados Unidos, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Estados Unidos, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Estados Unidos, 59901
- Logan Health Medical Center
-
Missoula, Montana, Estados Unidos, 59804
- Community Medical Center
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Estados Unidos, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Estados Unidos, 89183
- OptumCare Cancer Care at Fort Apache
-
-
New Jersey
-
New Brunswick, New Jersey, Estados Unidos, 08903
- Rutgers Cancer Institute of New Jersey
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Buffalo, New York, Estados Unidos, 14263
- Roswell Park Cancer Institute
-
Mineola, New York, Estados Unidos, 11501
- NYU Langone Hospital - Long Island
-
New York, New York, Estados Unidos, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Estados Unidos, 43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus, Ohio, Estados Unidos, 43228
- Doctors Hospital
-
Columbus, Ohio, Estados Unidos, 43215
- Grant Medical Center
-
Dayton, Ohio, Estados Unidos, 45415
- Dayton Physician LLC - Englewood
-
Delaware, Ohio, Estados Unidos, 43015
- Delaware Health Center-Grady Cancer Center
-
Delaware, Ohio, Estados Unidos, 43015
- Grady Memorial Hospital
-
Dublin, Ohio, Estados Unidos, 43016
- Dublin Methodist Hospital
-
Dublin, Ohio, Estados Unidos, 43016
- Columbus Oncology and Hematology Associates
-
Kettering, Ohio, Estados Unidos, 45429
- Kettering Medical Center
-
Mansfield, Ohio, Estados Unidos, 44903
- OhioHealth Mansfield Hospital
-
Marion, Ohio, Estados Unidos, 43302
- OhioHealth Marion General Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Ontario, Oregon, Estados Unidos, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Portland, Oregon, Estados Unidos, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Estados Unidos, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19107
- Thomas Jefferson University Hospital
-
Willow Grove, Pennsylvania, Estados Unidos, 19090
- Asplundh Cancer Pavilion
-
-
South Carolina
-
Boiling Springs, South Carolina, Estados Unidos, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Easley, South Carolina, Estados Unidos, 29640
- Prisma Health Cancer Institute - Easley
-
Greenville, South Carolina, Estados Unidos, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Estados Unidos, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Estados Unidos, 29605
- Prisma Health Cancer Institute - Butternut
-
Greer, South Carolina, Estados Unidos, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, Estados Unidos, 29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Rapid City, South Dakota, Estados Unidos, 57701
- Rapid City Regional Hospital
-
-
Tennessee
-
Bristol, Tennessee, Estados Unidos, 37620
- Bristol Regional Medical Center
-
Johnson City, Tennessee, Estados Unidos, 37604
- Regional Cancer Center at Johnson City Medical Center
-
Kingsport, Tennessee, Estados Unidos, 37660
- Ballad Health Cancer Care - Kingsport
-
Kingsport, Tennessee, Estados Unidos, 37660
- Wellmont Holston Valley Hospital and Medical Center
-
Nashville, Tennessee, Estados Unidos, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Temple, Texas, Estados Unidos, 76508
- Scott and White Memorial Hospital
-
-
Virginia
-
Bristol, Virginia, Estados Unidos, 24201
- Ballad Health Cancer Care - Bristol
-
Charlottesville, Virginia, Estados Unidos, 22908
- University of Virginia Cancer Center
-
Richmond, Virginia, Estados Unidos, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Estados Unidos, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98122
- Swedish Medical Center-First Hill
-
-
West Virginia
-
Charleston, West Virginia, Estados Unidos, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Appleton, Wisconsin, Estados Unidos, 54911
- ThedaCare Regional Cancer Center
-
Ashland, Wisconsin, Estados Unidos, 54806
- Duluth Clinic Ashland
-
Berlin, Wisconsin, Estados Unidos, 54923
- ThedaCare Cancer Care - Berlin
-
Burlington, Wisconsin, Estados Unidos, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Cudahy, Wisconsin, Estados Unidos, 53110
- Aurora Saint Luke's South Shore
-
Germantown, Wisconsin, Estados Unidos, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Estados Unidos, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Estados Unidos, 54311
- Aurora BayCare Medical Center
-
Janesville, Wisconsin, Estados Unidos, 53548
- Mercyhealth Hospital and Cancer Center - Janesville
-
Kenosha, Wisconsin, Estados Unidos, 53142
- Aurora Cancer Care-Kenosha South
-
La Crosse, Wisconsin, Estados Unidos, 54601
- Gundersen Lutheran Medical Center
-
Madison, Wisconsin, Estados Unidos, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Madison, Wisconsin, Estados Unidos, 53718
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Marinette, Wisconsin, Estados Unidos, 54143
- Aurora Bay Area Medical Group-Marinette
-
Milwaukee, Wisconsin, Estados Unidos, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Estados Unidos, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Estados Unidos, 53233
- Aurora Sinai Medical Center
-
Neenah, Wisconsin, Estados Unidos, 54956
- ThedaCare Regional Medical Center - Neenah
-
New London, Wisconsin, Estados Unidos, 54961
- ThedaCare Cancer Care - New London
-
Oshkosh, Wisconsin, Estados Unidos, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Oshkosh, Wisconsin, Estados Unidos, 54904
- ThedaCare Cancer Care - Oshkosh
-
Racine, Wisconsin, Estados Unidos, 53406
- Aurora Cancer Care-Racine
-
Shawano, Wisconsin, Estados Unidos, 54166
- ThedaCare Cancer Care - Shawano
-
Sheboygan, Wisconsin, Estados Unidos, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Summit, Wisconsin, Estados Unidos, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, Estados Unidos, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Waupaca, Wisconsin, Estados Unidos, 54981
- ThedaCare Cancer Care - Waupaca
-
Wauwatosa, Wisconsin, Estados Unidos, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, Estados Unidos, 53227
- Aurora West Allis Medical Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-E5 based on the presence of an actionable mutation as defined in EAY191
-
Patient must be enrolled on the ComboMATCH Registration Protocol (EAY191) at the time of registration/randomization to the EAY191-E5 study
-
Patient must be >= 18 years of age
-
Patient must have a KRAS G12C alteration as determined by the ComboMATCH screening assessment
-
Patient must have disease that can be safely biopsied and agree to a pre-treatment biopsy or have tissue available from within 12 months prior to the date of registration on the ComboMATCH Registration Trial (EAY191-E5)
- NOTE: The current actionable marker of interest (aMOI)/actionable alteration list for this treatment trial can be found on the Cancer Trials Support Unit (CTSU) website: www.ctsu.org (final URL pending)
- NOTE: Novel/Dynamic aMOI can be submitted for review per the process described in the ComboMATCH registration protocol
-
Patient must have cytologically/histologically confirmed advanced/metastatic solid tumor
-
Patient must have progressed on at least one line of standard of care therapy in the advanced/metastatic setting
- NOTE: Patients who have progressed on a prior human epidermal growth factor receptor (EGFR) inhibitor will meet this criterion
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2 (or Karnofsky performance status >= 60%)
-
Patient must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) documented by imaging obtained within 28 days prior to registration/randomization
-
Patient must not have any serious active infection within 4 weeks prior to EAY191-E5 registration/randomization (e.g., requiring hospitalization and/or intravenous [IV] antibiotics) or currently receiving oral or IV antibiotics for the treatment of infection. Patients receiving prophylactic antibiotics are eligible
-
Patient must have the ability to retain oral medication and not have any clinically significant gastrointestinal abnormalities that might alter absorption
-
Patient must not have any history of or current evidence of non-infectious interstitial lung disease (ILD)/pneumonitis
-
Patient must not have a history of allergic reactions attributed to either of the study agents or to agents of similar chemical or biologic composition
-
Patient must have completed full treatment cycle 21 days prior to EAY191-E5 registration/randomization if they have received prior chemotherapy, biological cancer therapy, radiation therapy or an investigational agent/device. Patients must have recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or better from any adverse events due to prior cancer therapy (with the exception of alopecia)
-
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration/randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patient must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for at least 6 months after the last dose of protocol treatment. Patients must not breastfeed while receiving protocol treatment and for one week (7 days) after the last dose of AMG 510 (sotorasib) and 2 months after the last dose of panitumumab
-
Patients must not have neuropathy ≥ grade 2 within 14 days prior to registration/randomization
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
-
Human immunodeficiency virus (HIV)-infected patients no effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients with known history or current symptoms of cardiac history, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trail, patients should be class 2B or better
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (obtained ≤ 28 days prior to protocol registration/randomization)
-
Aspartate aminotransferase (AST) (serum (glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase ([SGPT]) < 3 x institutional upper limit of normal (obtained ≤ 28 days prior to protocol registration/randomization)
-
Creatinine =< 1.5 x institutional ULN OR creatinine clearance > 50 mL/min/1.73 m^2 for patients with creatinine levels > 1.5 mg/dL as per Cockcroft-Gault (obtained ≤ 28 days prior to protocol registration/randomization)
-
COHORT I: Patient must not have colorectal cancer or non-small cell lung cancer
-
COHORT I: Patient must not have been previously treated with a KRAS G12C inhibitor
-
COHORT II: Patient must have progressed after treatment at the recommended phase II dose (RP2D) of any KRAS G12C inhibitor
- NOTE: Patients on cohort 1 who experience progression on Regimen 2 (AMG 510 [sotorasib] alone) may be eligible to enroll on cohort 2 and receive combination treatment with panitumumab and AMG 510 (sotorasib). Patients must meet performance status requirements and laboratory values as above and must be begin treatment within 7 days of enrollment. Migration to cohort 2 must take place within 6 months of progression, with no intervening anti-cancer therapy given.
- NOTE: Cohort migration following disease progression is dependent on a slot being available. MATCHBox makes the new treatment assignment following initiation of a step 2 registration for this treatment trial
-
COHORT II: Patient must not have been previously treated with a KRAS G12C inhibitor in combination with an EGFR inhibitor
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Cohort I Arm A (sotorasib, panitumumab)
Patients receive sotorasib PO QD on days 1-28 and panitumumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study. |
Undergo MRI
Outros nomes:
Undergo collection of blood
Outros nomes:
Undergo CT scan
Outros nomes:
Undergo tumor biopsy
Outros nomes:
Given IV
Outros nomes:
Given PO
Outros nomes:
|
|
Comparador Ativo: Cohort I Arm B (sotorasib)
Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study. |
Undergo MRI
Outros nomes:
Undergo collection of blood
Outros nomes:
Undergo CT scan
Outros nomes:
Undergo tumor biopsy
Outros nomes:
Given PO
Outros nomes:
|
|
Experimental: Cohort II (sotorasib, panitumumab)
Patients receive combination therapy as in Arm A. |
Undergo MRI
Outros nomes:
Undergo collection of blood
Outros nomes:
Undergo CT scan
Outros nomes:
Undergo tumor biopsy
Outros nomes:
Given IV
Outros nomes:
Given PO
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Progression-free survival (PFS) (Cohort I)
Prazo: From registration to documented disease progression or death from any cause, assessed up to 3 years
|
PFS will be compared between the arms using a one-sided log rank test with 10% type I error. Cox's proportional hazards model will be used to estimate the PFS hazard ratio between the treatment arms and a two-sided 80% confidence interval will be reported (to correspond to the one-sided 10% type I error). Confidence intervals on most other quantities will use the two-sided 90% level. |
From registration to documented disease progression or death from any cause, assessed up to 3 years
|
|
Best objective response (Cohort II)
Prazo: From the start of the treatment until disease progression/recurrence, assessed up to 3 years
|
Will be evaluated using the criteria defined by Response Evaluation Criteria in Solid Tumors) version 1.1 for patients with solid tumors. |
From the start of the treatment until disease progression/recurrence, assessed up to 3 years
|
|
Overall response rate (ORR) (Cohort II)
Prazo: From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years
|
The exact 90% confidence interval on the ORR (determined using the method of Atkinson and Brown) will be reported. If the number of analyzable cases is less than 35, a 5% one-sided test will still be used. |
From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Overall survival (OS) (Cohort I)
Prazo: Up to 3 years
|
OS distributions by treatment will be estimated and 90% confidence intervals on estimated rates at 6 and 12 months will be reported. The OS hazard ratio will be estimated using Cox proportional hazards model and a 90% confidence interval reported. |
Up to 3 years
|
|
ORR (Cohort I)
Prazo: Up to 3 years
|
Will be compared using Fisher's exact test and exact 90% confidence intervals for the rates in each arm will be computed. |
Up to 3 years
|
|
Disease control rates (Cohort I)
Prazo: From the start of the treatment until the criteria for progression are met, assessed up to 3 years
|
Will be compared using Fisher's exact test and exact 90% confidence intervals for the rates in each arm will be computed. |
From the start of the treatment until the criteria for progression are met, assessed up to 3 years
|
|
PFS (Cohort II)
Prazo: At 6 and 12 months, assessed up to 3 years
|
Will be estimated and 90% confidence intervals on estimated rates will be reported. |
At 6 and 12 months, assessed up to 3 years
|
|
OS (Cohort II)
Prazo: At 6 and 12 months, assessed up to 3 years
|
Will be estimated and 90% confidence intervals on estimated rates will be reported. |
At 6 and 12 months, assessed up to 3 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Kristen R Spencer, ECOG-ACRIN Cancer Research Group
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Processos Patológicos
- Neoplasias
- Processos Neoplásicos
- Condições Patológicas, Sinais e Sintomas
- Neoplasia Metástase
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Técnicas de investigação
- Técnicas de laboratório clínico
- Técnicas e procedimentos de diagnóstico
- Diagnóstico
- Procedimentos cirúrgicos, operatórios
- Técnicas citológicas
- Citodiagnóstico
- Anticorpos, monoclonais, humanizados
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Técnicas de diagnóstico, cirúrgico
- Técnicas de química, analíticas
- Análise de espectro
- Panitumumabe
- Biópsia
- Manipulação de amostras
- Espectroscopia de ressonância magnética
- Sotorasib
Outros números de identificação do estudo
- NCI-2022-09876
- U10CA180820 (Concessão/Contrato do NIH dos EUA)
- NCI-2022-09876 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- EAY191-E5 (Outro identificador: CTEP)
- EAY191-E5 (Outro identificador: ECOG-ACRIN Cancer Research Group)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .